Medicine / Health / BioPharma / Industrial / Fuel / Genome / Biopharma / Drug / Drugs / Genomics / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / AbbVie / AC Immune / Acquisition / Alliances / Alphabet / American Hpspital Association / American Medical Association / Atlas Ventures / bacteriophage / Baseline / Bioscicience / Biotech / Bristol-myers Squibb / CAR-T chimeric antigen receptor / CD39 / Celgene / ceo / Chris Lowe / CMO / commissioner / Cortexyme / CRISPR-Cas3 / CSO / Cydan / delay / Drug Development / drug price / early detection / Eric Dube / FDA / Filing / fundraising / Gene editing / genome editingr / Google Life Sciences / high / Immunotherapy / Infection / IPO / J.P. Morgan Healthcare / Jazz Pharmaceuticals Codiak / Johnson & Johnson / Life Sciences / Locus Biosciences / Lung Cancer / M&A / Manufacturing / Marie Kosco-Vilbois / Martin Shkreli / Merck / Michael Detke / NASH type 2 diaebets / NGM313 / Oliver Rosen / Ontario Teacher' Pension Plan / Partnerships / plan / Private Equity / proposal / Retrophin / Scott Gottlieb / shutdown / Silver Lake / SMO / SQZ Biotechnologies / Stephen Aselange / supplemental fund / TCR2 therapeutics / Tiburio Therapeutics / Tizona Therapeutics / Trump administration / VC / Venture Capital / VeraCyte / Verily

Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

Posted on: Jan 4, 2019   |   Posted by: Biotech Mag Top

Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy, and more. You'll find a few of our favorite...

Continue reading ...



Other Posts from Biotech Mag Top